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Antibody responses to flagellin C 
and Streptococcus gallolyticus pilus 
proteins in colorectal cancer
Julia Butt1,2, Nerea Fernández de Larrea3,4, Harold Tjalsma5, Rian Roelofs6, Ikuko Kato7, 
Vicente Martín  4,8, Beatriz pérez-Gómez  3,4,9, Victor Moreno  4,10,11,12, Trinidad  
Dierssen-sotos4,13, Jesús Castilla 4,14, Guillermo Fernández-Tardón4,15, Pilar Amiano4,16, 
Dolores Salas4,17,18, Juan Alguacil4,19, José Juan Jiménez-Moleón  4,20,21, José María Huerta4,22, 
Silvia de Sanjosé4,23,24, Rosa del Campo  25,26, Manolis Kogevinas4,27,28,29, Marina Pollán3,4, 
Michael Pawlita1, Tim Waterboer1, Annemarie Boleij  30 & Nuria Aragonés4,31
Antibodies to Streptococcus gallolyticus subspecies gallolyticus (SGG) have been associated with 
colorectal cancer (CRC). Because SGG may correlate with impaired gut epithelia, we assessed the 
association of antibodies to bacterial flagellin C (FliC), a measure potentially related to this impairment, 
with CRC and the CRC-specific interaction with antibodies to SGG proteins. Antibodies to FliC and SGG 
pilus proteins Gallo2178 and Gallo2179 were measured in two independent studies, a combined study 
from Nijmegen and Detroit (93 CRC cases, 74 controls) and a replication data set including 576 cases and 
576 controls from the Spanish multicenter multicase-control study (MCC-Spain). Logistic regression was 
applied to assess whether antibodies to FliC were associated with CRC and modified the association of 
antibodies to SGG proteins with CRC. Antibodies to FliC were associated with those to SGG Gallo2178 
among CRC cases, resulting in an interaction in the association of antibodies to Gallo2178 with CRC 
(p = 0.007). This association was only present among individuals with high antibody responses to FliC 
(OR: 2.42, 95% CI: 1.45–4.06). In conclusion, our findings suggest that colorectal tumorigenesis could 
be accompanied by an impaired integrity of the epithelium that could result in associated increased 
antibody responses to bacterial proteins.
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Colorectal cancer (CRC) is the fourth most common cancer worldwide with in total 1.36 million newly diagnosed 
cases in 20121. Risk factors include older age, male sex, certain dietary habits, tobacco and alcohol consump-
tion, obesity, family history of CRC as well as history of inflammatory bowel diseases2. Interest in a potential 
association of bacteria residing in the gut with CRC development has increased during the past years3,4. In par-
ticular, Streptococcus gallolyticus subspecies gallolyticus (SGG) was shown to be associated with CRC in several 
epidemiological studies but also in some mechanistic studies5–14. Boleij et al. showed that antibody responses to 
SGG pilus proteins Gallo2178 and Gallo2179, both being hypothesized to be involved in virulence of the bacte-
rium15,16, were selectively detectable in adenoma and CRC cases in two studies from Nijmegen (Netherlands), and 
Detroit (USA)6. We reproduced this finding in two case-control studies, including a subset of the multicentric 
multicase-control study MCC-Spain, as well as one prospective study and demonstrated a significant association 
of antibody responses to Gallo2178 and Gallo2179 with an approximately 2-fold increased risk of developing 
CRC8,9,12.
SGG is a rare gut microbe in humans and occasionally causes systemic infection, facilitated by increased 
mucosal permeability, as seen in tumor development, as well as by strain specific virulence4. An impaired gut bar-
rier, however, should also enable other organisms to invade the otherwise well-protected gut epithelium. Bacterial 
products like lipopolysaccharide (LPS), also called endotoxin, or motility-proteins like flagellin C (FliC) are 
wide-spread among bacterial species and upon infection are targets of the host immune system17. Several stud-
ies assessed the association of these common bacterial products with diseases of the gut, e.g. Crohn’s disease or 
CRC and its precursors7,18–21. Kang et al. found that individuals with high plasma endotoxin levels had a 1.4-fold 
increased risk of having adenomas20, and Kong et al. found that high levels of antibody responses to Escherichia 
coli (E. coli) LPS and FliC were prospectively associated with CRC in men (OR: 1.66, 95% CI: 1.10–2.51)19. In two 
other studies from the Netherlands and USA, Salmonella FliC was associated with colorectal adenomas (OR 4.71, 
95% CI 1.10–20.14) and carcinomas (OR 3.09, 95% CI 1.22–7.79), while endotoxin levels were not7,21.
Using serological data obtained in the CRC and adenoma case-control studies from Nijmegen and Detroit and 
data obtained in MCC-Spain as a replication study, we here assessed whether antibody responses to FliC were 
simultaneously associated with CRC and with antibody responses to Gallo2178 and Gallo2179, as suggested by 
the gut permeability hypothesis.
Results
Association of antibody responses to FliC with CRC. In the Nijmegen/Detroit study, the OR for ade-
noma/CRC significantly increased with higher FliC quartile (ptrend = 0.011) with a statistically significant associ-
ation of the fourth versus the first quartile (OR: 2.32, 95% CI: 1.01–5.33) (Table 1, see Supplementary Table S2 for 
individual studies). In the replication study MCC-Spain, the OR for CRC did not show a positive trend, although 
the highest risk was found in the highest FliC quartile (Q4 vs Q1, OR: 1.14, 95% CI: 0.81–1.59).
Association of antibody responses to FliC with antibody positivity to SGG pilus proteins 
Gallo2178 and Gallo2179. We assessed in both studies, Nijmegen/Detroit and MCC-Spain, whether 
positivity to SGG pilus proteins was associated with antibody responses to FliC. In the total population of the 
Nijmegen/Detroit study, there was an association between antibody response to FliC and positivity to Gallo2179 
(p = 0.040) but not to Gallo2178 (p = 0.072) (Table 2). However, when analyzing cases and controls separately we 
observed that antibody positivity to Gallo2178 and Gallo2179 were significantly associated with FliC antibody 
response among cases (p = 0.023 and p = 0.021, respectively) but not among controls (p = 0.658 and p = 0.471, 
respectively) (see Supplementary Table S3 for individual studies).
In the replication study MCC-Spain, we partly reproduced the findings observed in the Nijmegen/Detroit 
study (Table 2): While there was no association between FliC quartile and positivity to neither Gallo2178 nor 
to Gallo2179 in the whole population, antibody positivity to Gallo2178 was significantly associated with FliC 
antibody response among cases (p = 0.011). The majority of cases positive for Gallo2178 (88% in the Nijmegen/
Detroit study and 71% in MCC-Spain) had simultaneously antibody responses to FliC in the upper quartiles 3 
and 4 (>379.5 MFI).
Association of antibody responses to SGG Gallo2178 and Gallo2179 with CRC stratified by 
FliC antibody response in MCC-Spain. The abovementioned analysis revealed a significant association 
between antibody positivity to SGG proteins with high antibody responses to FliC only among CRC cases. We 
performed an analysis of the association between antibody responses to SGG pilus proteins and CRC stratified 
by median MFI to FliC. The analysis was performed in the MCC-Spain study only since the sample size of the 
Nijmegen/Detroit study did not allow analysis with sufficient statistical power.
Among individuals with antibody responses to FliC below the median MFI, the association between antibody 
responses to SGG pilus proteins and CRC was absent (Gallo2178: OR: 0.85, 95%CI: 0.48–1.49; Gallo2179: OR: 
1.26, 95% CI: 0.72–2.20) (Table 3). However, among individuals with an antibody response to FliC above the 
median MFI, the OR for CRC with antibody positivity to Gallo2178 and Gallo2179 was increased and reached 
statistical significance for Gallo2178 (Gallo2178: OR: 2.42, 95%CI: 1.45–4.06; Gallo2179: OR: 1.63, 95% CI: 0.99–
2.68). This interaction was significant for Gallo2178 (pinteraction = 0.007).
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Discussion
In this study we assessed the association of antibody responses to FliC with CRC as well as a potential interaction 
with antibody responses to SGG pilus proteins Gallo2178 and Gallo2179. We found a significant trend for higher 
antibody responses to FliC in CRC cases compared to controls in the Nijmegen/Detroit study, which could not be 
Study FliC Total n (%) Controls n (%) Casesa n (%) OR (95%CI)b ptrend
Nijmegen/Detroit studies
Q1 38 (23) 19 (26) 19 (20) ref
Q2 29 (17) 19 (26) 10 (11) 0.53 (0.20–1.43)
Q3 37 (22) 17 (23) 20 (22) 1.18 (0.48–2.91)
Q4 63 (38) 19 (26) 44 (47) 2.32 (1.01–5.33) 0.011
MCC-Spain
Q1 296 (26) 145 (25) 151 (26) ref
Q2 254 (22) 143 (25) 111 (19) 0.75 (0.53–1.06)
Q3 288 (25) 144 (25) 144 (25) 0.99 (0.70–1.38)
Q4 314 (27) 144 (25) 170 (30) 1.14 (0.81–1.59) 0.247
Table 1. Association of antibody response to FliC with adenoma/CRC in the Nijmegen/Detroit and MCC-
Spain studies. aCases include n = 23 adenoma and n = 70 CRC cases for Nijmegen/Detroit studies, all cases were 
CRC in MCC Spain; bLogistic regression model, Nijmegen/Detroit study: no further adjustment, MCC-Spain: 
adjustment for age, sex, province, education, BMI, smoking and family history of CRC; significant associations 
(p-value < 0.05) are marked in bold font; Q = quartile.
FliC quartile
Gallo2178
p-valueb
Gallo2179
p-valuebneg n (%) pos n (%) neg n (%) pos n (%)
Nijmegen/Detroit studies
Total 150 (100) 17 (100) 151 (100) 16 (100)
    Q1 36 (24) 2 (12) 35 (23) 3 (19)
    Q2 27 (18) 2 (12) 28 (19) 1 (6)
    Q3 29 (19) 8 (47) 29 (19) 8 (50)
    Q4 58 (39) 5 (29) 0.072 59 (39) 4 (25) 0.040
Controls 65 (100) 9 (100) 66 (100) 8 (100)
    Q1 17 (26) 2 (22) 16 (24) 3 (38)
    Q2 18 (28) 1 (11) 18 (27) 1 (13)
    Q3 14 (22) 3 (33) 14 (21) 3 (38)
    Q4 16 (25) 3 (33) 0.658 18 (27) 1 (13) 0.471
Casesa 85 (100) 8 (100) 85 (100) 8 (100)
    Q1 19 (22) 0 (0) 19 (22) 0 (0)
    Q2 9 (11) 1 (13) 10 (12) 0 (0)
    Q3 15 (18) 5 (63) 15 (18) 5 (63)
    Q4 42 (49) 2 (25) 0.023 41 (48) 3 (37) 0.021
MCC-Spain
Total 1012 (100) 140 (100) 1015 (100) 137 (100)
    Q1 268 (26) 28 (20) 269 (27) 27 (20)
    Q2 226 (22) 28 (20) 225 (22) 29 (21)
    Q3 247 (24) 41 (29) 250 (25) 38 (28)
    Q4 271 (27) 43 (31) 0.242 271 (27) 43 (31) 0.300
Controls 519 (100) 57 (100) 520 (100) 56 (100)
    Q1 130 (25) 15 (26) 135 (26) 10 (18)
    Q2 126 (24) 17 (30) 127 (24) 16 (29)
    Q3 132 (25) 12 (21) 126 (24) 18 (32)
    Q4 131 (25) 13 (23) 0.757 132 (25) 12 (21) 0.354
Casesa 493 (100) 83 (100) 495 (100) 81 (100)
    Q1 138 (28) 13 (16) 134 (27) 17 (21)
    Q2 100 (20) 11 (13) 98 (20) 13 (16)
    Q3 115 (23) 29 (35) 124 (25) 20 (25)
    Q4 140 (28) 30 (36) 0.011 139 (28) 31 (38) 0.268
Table 2. Antibody response to FliC and association with SGG Gallo2178 and Gallo2179 antibody positivity. 
aCases include n = 23 adenoma and n = 70 CRC cases for Nijmegen/Detroit studies, all cases were CRC in MCC 
Spain; bChi-Square test; significant associations (p-value < 0.05) are marked in bold font.
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reproduced in the replication study MCC-Spain. However, antibody responses to FliC were associated with anti-
body responses to SGG pilus protein Gallo2178 in CRC cases of both studies resulting in a significantly stronger 
association of CRC with antibody positivity to Gallo2178 among individuals with high antibody responses to FliC 
compared to those exhibiting low responses to FliC.
FliC is a motility protein conserved among several gram-negative bacteria including Salmonella and 
Escherichia coli. It is recognized by the host immune system, specifically by TLR5, when it crosses the gut epithe-
lium as it might be given in the case of a disturbed gut epithelial integrity as a result of a developing tumor22. We 
hypothesize that increased gut permeability in CRC development is related to an increased immune response to 
certain gut bacteria and that therefore antibody responses to FliC and CRC-related SGG Gallo2178 and Gallo2179 
will be increased and correlated in CRC cases in contrast to controls. Our results support this hypothesis since 
antibody responses to SGG Gallo2178 were specifically associated with CRC in the presence of those to FliC, sug-
gesting increased antigen sampling by the immune system. In this respect, the association of CRC with antibodies 
to bacterial proteins could be attributed to a complex interplay of several bacteria rather than to a single bacterial 
species, either invading colorectal tissue simultaneously or consecutively dependent on tumor development as 
proposed in the bacteria-driver passenger model4. Certain bacteria might simply be bystanders without influence 
on CRC development, while others might contribute to progression, e.g. by induction of inflammation.
SGG has previously been shown to promote tumor growth, in vitro using cell lines but also in vivo in mouse 
models. SGG may benefit from cancer metabolites in the tumor environment, and may shape its own niche envi-
ronment in the developing tumor11,13–15. The effects on cell proliferation are correlated with adherence abilities 
of the respective SGG strains to the epithelium and can depend on the encoded pili, i.e. those expressed from 
loci pil1 (Gallo2178 and Gallo2179), pil2 and pil316. Furthermore, certain strain dependencies within SGG might 
relate to unidentified virulence factors besides pil1–3 to adhere to and colonize colon epithelia of CRC patients13. 
Comparative genomics of eight SGG strains from human blood and feces recently revealed that complete pil1-3 
loci are only present in SGG causing bacteremia and/or endocarditis, while the fecal SGG may carry truncated 
versions of the pil1-3 loci23,24. This could also explain the fact that not every patient with a high FliC-titer also 
expresses measurable antibody responses towards both, Gallo2178 and Gallo2179.
A major strength of this work is the analysis of two separate studies, the Nijmegen/Detroit study as well as 
MCC-Spain as a replication study, which allowed us to assess reproducibility of the results in studies that were 
independently conducted. Their differences in study design and serological methodology applied, however, could 
also have led to the observed association of antibody responses to FliC with adenoma/CRC being present in the 
Nijmegen/Detroit study only. The Nijmegen/Detroit study included adenoma patients and stage I and II CRC 
cases whereas MCC-Spain comprised only CRC cases, including all stages. We performed an analysis separately 
by stage (stage I/II versus stage III/IV) in MCC-Spain and found no difference in the association of antibody 
responses to FliC with CRC by stage (data not shown). However, it still remains to be elucidated whether these 
bacteria have a role primarily in adenoma development. Furthermore, as described above, different SGG strains 
exhibit a distinct virulence potential by differential expression of pilus loci. In addition, the natural history of 
antibody responses raised against different proteins of SGG is unknown. Longitudinal studies are needed to give 
further insight when in relation to CRC development sero-conversion to the respective bacterial proteins appears 
and whether this could even differ in time for proteins of the same pilus loci. The effect on the reported associa-
tions of using ELISA in the Nijmegen/Detroit study as opposed to multiplex serology in MCC-Spain cannot be 
determined from the given data since direct comparisons with both assays in the same samples were not available. 
We therefore cannot exclude that the applied serological method further may have affected the observed differ-
ences in results between studies.
A further limitation of this study was the design and small sample size of the Nijmegen/Detroit study. We 
combined two independent small studies, one from Nijmegen and one from Detroit (Supplementary Tables S2 
and S3). Additionally, adjusting for potential confounders was only possible in the replication study MCC-Spain. 
Antigen Controls n (%) Cases n (%) OR (95%CI)a p-valuea pinteraction
Overall Gallo2178 Neg 519 (90) 493 (86)
Pos 57 (10) 83 (14) 1.57 (1.09–2.27) 0.016
FliC Q1/Q2 Gallo2178 Neg 256 (89) 238 (91)
Pos 32 (11) 24 (9) 0.85 (0.48–1.49) 0.564
FliC Q3/Q4 Gallo2178 Neg 263 (91) 255 (81)
Pos 25 (9) 59 (19) 2.42 (1.45–4.06) 0.0007 0.007
Overall Gallo2179 Neg 520 (90) 495 (86)
Pos 56 (10) 81 (14) 1.46 (1.01–2.11) 0.045
FliC Q1/Q2 Gallo2179 Neg 262 (91) 232 (89)
Pos 26 (9) 30 (11) 1.26 (0.72–2.20) 0.427
FliC Q3/Q4 Gallo2179 Neg 258 (90) 263 (84)
Pos 30 (10) 51 (16) 1.63 (0.99–2.68) 0.056 0.499
Table 3. Association of SGG pilus proteins Gallo2178 and Gallo2179 with CRC, overall and stratified by FliC 
median antibody response in MCC-Spain. aLogistic regression model with adjustment for age, sex, province, 
education, BMI, smoking and family history of CRC; significant associations (p-value < 0.05) are marked in 
bold font.
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The low number of sero-positives (e.g. n = 83 Gallo2178 and n = 81 Gallo2179 sero-positive cases in MCC-Spain) 
further refrained us from analyzing the antibody responses to Gallo2178 and Gallo2179 in quartiles in relation 
to FliC quartiles. This analysis of a correlation between antibody level to FliC and Gallo2189 and Gallo2179 
would further strengthen the reported results but needs larger datasets for sufficient statistical power. In addition, 
reverse causality cannot be excluded in a case-control study and the results presented here need to be verified in 
prospective studies.
In conclusion, we demonstrated that antibody responses to SGG pilus protein Gallo2178 were associated with 
antibody responses to FliC specifically in CRC cases. This finding suggests that CRC development may be asso-
ciated with increased gut permeability and concomitant antibody responses to specific CRC-associated bacteria, 
like SGG.
Methods
Study population. Nijmegen and detroit studies. The study populations have been described pre-
viously6,7,21. Serum samples from 37 stage I/II CRC and 12 adenoma patients, who had been admitted to the 
Radboud University Medical Center (Nijmegen, the Netherlands) were collected. Serum from 27 healthy blood 
donors >50 years of age were used as controls. Plasma samples from patients who participated in a popula-
tion-based case-control study in Metropolitan Detroit (USA) were included in the study comprising 26 stage I/
II CRC patients, 7 CRC patients with unknown stage, 11 adenoma patients and 47 healthy controls. The use of 
the samples was approved by the local medical ethical committees (CMO Nijmegen/Arnhem #2006/078 and 
Wayne State University Human Investigation Committee #0409000504). Serum and plasma samples were stored 
at −80 °C until use.
MCC-Spain study. MCC-Spain is a multicentric multicase-control study assessing the impact of environmen-
tal exposures and their interaction with genetic factors on five cancers in Spain8,25. Individuals with histologi-
cally confirmed malignant disease were recruited between 2008 and 2013 in hospitals of 12 Spanish provinces. 
Controls free of these cancers were randomly sampled from general practitioner’s lists at primary health centers 
located in the catchment areas of the hospitals where cases were recruited and frequency-matched to cases by age, 
sex and province. Participants completed a questionnaire through personal interview and donated a blood sam-
ple. For the present study, 576 CRC cases and 576 controls were analyzed. Population characteristics are shown 
in Supplementary Table S1.
The protocol of MCC-Spain was approved by the Clinical Research Ethic Committee of the Clínico San 
Carlos Hospital, the Clinical Research Ethic Committee of the Ramón y Cajal Hospital, the Clinical Research 
Ethic Committee of the Municipal Healthcare Institute of Barcelona, the Clinical Research Ethic Committee of 
Navarra, and the Research and Animal Well-being Ethic Committee of the Carlos III Health Institute. All the 
procedures contributing to this work comply with the ethical standards of the relevant national and institutional 
committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All partic-
ipants signed an informed consent.
Gallo2178, Gallo2179 and FliC ELISA. The ELISA assays for Gallo2178, Gallo2179 and FliC have been 
described previously6,7,21. In short, ELISA-plates were coated with FliC (InvivoGen, San Diego, CA, USA), 
or nickel-affinity purified recombinant expressed proteins Gallo2178 or Gallo2179 (antigen, Ag)6. For each 
antigen-coated well, a second well on the same plate was incubated with coating buffer without antigen (blank). 
Serum or plasma samples were added to the wells and incubated. Bound serum antibodies were detected using 
horseradish peroxidase (HRP)-labeled goat anti-human IgG (1:25.000; Jackson Immunoresearch). Optical den-
sity of the samples was measured in duplicate and titers were calculated as the mean OD450Ag − OD450blank 
and expressed as arbitrary FliC, Gallo2178 or Gallo2179 units based on reference samples from Salmonella 
typhimurium- (S. typhimurium), or S. gallolyticus-infected patients, respectively. Cut-off values for positive 
Gallo2179 and Gallo2178 response were set as published before with 78% specificity (Gallo2179 > 12.4 (Detroit), 
Gallo2179 > 9.2 (Nijmegen), Gallo2178 > 2.0 (Detroit) and Gallo2178 > 3.7 (Nijmegen)). Quartiles for FliC were 
calculated based on the FliC titers of the control group and set at Q1: <2.14, Q2: 2.14 −< 3.18, Q3: 3.18 −< 6.63, 
and Q4: ≥6.63 (Detroit) and Q1: <1.16, Q2: 1.16 −< 1.70, Q3: 1.70 −< 3.00, and Q4: ≥3.00 (Nijmegen).
Gallo2178, Gallo2179 and FliC multiplex serology. MCC-Spain serum samples were sent on dry 
ice to the German Cancer Research Center (DKFZ, Heidelberg, Germany) and analyzed in a final 1:500 dilu-
tion. Multiplex serology was performed as described previously8,26. His6-tagged recombinantly expressed and 
affinity-purified SGG pilus proteins Gallo2178 and Gallo21796 as well as S. typhimurium FliC (InvivoGen, San 
Diego, CA, USA) were directly cross-linked onto fluorescence-labeled polystyrene beads (SeroMap, Luminex 
Corp., Austin, TX, USA). Mixing of the different antigen-coupled bead sets allowed analysis of antibody 
responses in a serum against several antigens in one reaction. A Luminex analyser (Luminex Corp., Austin, TX, 
USA) distinguishes the bead sets and simultaneously quantifies the amount of bound serum antibody by a sec-
ondary antibody conjugated with a fluorescent reporter (Streptavidin-R-Phycoerythrin). The level of antibody 
response was given as median fluorescence intensity (MFI) of at least 100 beads per set measured.
Cut-off definition for antibody responses to SGG Gallo2178 and Gallo2179 was arbitrary as previously 
described8 and defined 10% of controls as positive (cut-off: Gallo2178: 21 MFI; Gallo2179: 506 MFI). Antibody 
responses to FliC were analyzed in quartiles as defined in controls (Q1: ≤159 MFI; Q2: 159.5–379.5 MFI; Q3: 
380–938.5 MFI; Q4: >938.5 MFI).
Statistical analysis. Nijmegen and Detroit studies were analyzed as a combined study in the main analysis 
to increase statistical power.
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Associations between antibody responses to FliC, and Gallo2178 and Gallo2179 in the Nijmegen/Detroit 
study and in the MCC-Spain study were analyzed using a Chi-square test.
Associations of antibody responses to FliC, Gallo2178 and Gallo2179 with CRC were assessed using logistic 
regression models to compute odds ratios (OR) and 95% confidence intervals (95% CI). A p-value of <0.05 was 
considered statistically significant. For the Nijmegen/Detroit studies, additional sociodemographic information 
was available only for part of the samples and thus no further adjustment was performed. For the replication in 
the MCC-Spain study, multivariable logistic regression models were applied with adjustment for age, sex, prov-
ince, education (low (primary school or lower), intermediate (secondary school), high (University)), BMI (kg/
m2, <25, 25 −< 30, ≥30), smoking (never, former, current) and family history of CRC in first or second-degree 
relatives. In the MCC-Spain study, we further performed a stratified analysis by median FliC MFI (379.5 MFI) to 
address whether antibody responses to FliC affected the association of antibody positivity to SGG pilus proteins 
with CRC. We added an interaction term between FliC (below/above median MFI) and Gallo2178 or Gallo2179 
antibody positivity and performed a likelihood ratio test to assess statistical significance.
Data Availability
The authors confirm that the study data of the Nijmegen/Detroit studies are available as supplementary material. 
The study data of MCC-Spain is available only upon reasonable request to Nerea Fernández de Larrea (nfernan-
dez@isciii.es) due to personal data safety protection regulations.
References
 1. Ferlay, J. et al. GLOBOCAN 2012 v1.0,.Lyon, France: International Agency for Research on Cancer. Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 11 [Internet], http://globocan.iarc.fr (2013).
 2. Brenner, H., Kloor, M. & Pox, C. P. Colorectal cancer. Lancet 383, 1490–1502, https://doi.org/10.1016/S0140-6736(13)61649-9 
(2014).
 3. Ahn, J. et al. Human gut microbiome and risk for colorectal cancer. Journal of the National Cancer Institute 105, 1907–1911, https://
doi.org/10.1093/jnci/djt300 (2013).
 4. Tjalsma, H., Boleij, A., Marchesi, J. R. & Dutilh, B. E. A bacterial driver-passenger model for colorectal cancer: beyond the usual 
suspects. Nature reviews. Microbiology 10, 575–582, https://doi.org/10.1038/nrmicro2819 (2012).
 5. Abdulamir, A. S., Hafidh, R. R., Mahdi, L. K., Al-jeboori, T. & Abubaker, F. Investigation into the controversial association of 
Streptococcus gallolyticus with colorectal cancer and adenoma. BMC cancer 9, 403, https://doi.org/10.1186/1471-2407-9-403 
(2009).
 6. Boleij, A. et al. Selective antibody response to Streptococcus gallolyticus pilus proteins in colorectal cancer patients. Cancer Prev Res 
(Phila) 5, 260–265, https://doi.org/10.1158/1940-6207.CAPR-11-0321 (2012).
 7. Boleij, A. et al. Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer 116, 4014–4022, 
https://doi.org/10.1002/cncr.25212 (2010).
 8. Butt, J. et al. Association of Streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: Serological evidence. 
International journal of cancer. Journal international du cancer 138, 1670–1679, https://doi.org/10.1002/ijc.29914 (2016).
 9. Butt, J. et al. Serology of Streptococcus gallolyticus subspecies gallolyticus and its association with colorectal cancer and precursors. 
International journal of cancer. Journal international du cancer. https://doi.org/10.1002/ijc.30765 (2017).
 10. Garza-Gonzalez, E. et al. Immune response against Streptococcus gallolyticus in patients with adenomatous polyps in colon. 
International journal of cancer. Journal international du cancer 131, 2294–2299, https://doi.org/10.1002/ijc.27511 (2012).
 11. Kumar, R. et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS pathogens 13, e1006440, 
https://doi.org/10.1371/journal.ppat.1006440 (2017).
 12. Butt, J. et al. Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer. International 
journal of cancer. Journal international du cancer. https://doi.org/10.1002/ijc.31283 (2018).
 13. Kumar, R., Herold, J. L., Taylor, J., Xu, J. & Xu, Y. Variations among Streptococcus gallolyticus subsp. gallolyticus strains in 
connection with colorectal cancer. Scientific reports 8, 1514, https://doi.org/10.1038/s41598-018-19941-7 (2018).
 14. Aymeric, L. et al. Colorectal cancer specific conditions promote Streptococcus gallolyticus gut colonization. Proceedings of the 
National Academy of Sciences of the United States of America 115, E283–E291, https://doi.org/10.1073/pnas.1715112115 (2018).
 15. Boleij, A. et al. Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect 
Dis 203, 1101–1109, https://doi.org/10.1093/infdis/jiq169 (2011).
 16. Danne, C. et al. Molecular characterization of a Streptococcus gallolyticus genomic island encoding a pilus involved in endocarditis. 
J Infect Dis 204, 1960–1970, https://doi.org/10.1093/infdis/jir666 (2011).
 17. Sanders, C. J., Yu, Y., Moore, D. A. 3rd, Williams, I. R. & Gewirtz, A. T. Humoral immune response to flagellin requires T cells and 
activation of innate immunity. J Immunol 177, 2810–2818 (2006).
 18. Lodes, M. J. et al. Bacterial flagellin is a dominant antigen in Crohn disease. The Journal of clinical investigation 113, 1296–1306, 
https://doi.org/10.1172/JCI20295 (2004).
 19. Kong, S. Y. et al. Serum Endotoxins and Flagellin and Risk of Colorectal Cancer in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) Cohort. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology 25, 291–301, https://doi.org/10.1158/1055-9965.EPI-
15-0798 (2016).
 20. Kang, M. et al. Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC cancer 13, 91, 
https://doi.org/10.1186/1471-2407-13-91 (2013).
 21. Kato, I. et al. Partial associations of dietary iron, smoking and intestinal bacteria with colorectal cancer risk. Nutrition and cancer 65, 
169–177, https://doi.org/10.1080/01635581.2013.748922 (2013).
 22. Ramos, H. C., Rumbo, M. & Sirard, J. C. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. 
Trends in microbiology 12, 509–517, https://doi.org/10.1016/j.tim.2004.09.002 (2004).
 23. Pasquereau-Kotula, E., Martins, M., Aymeric, L. & Dramsi, S. Significance of Streptococcus gallolyticus subsp. gallolyticus 
Association With Colorectal Cancer. Frontiers in microbiology 9, 614, https://doi.org/10.3389/fmicb.2018.00614 (2018).
 24. Jans, C. & Boleij, A. The Road to Infection: Host-Microbe Interactions Defining the Pathogenicity of Streptococcus bovis/
Streptococcus equinus Complex Members. Front. Microbiol. 9, 603, https://doi.org/10.3389/fmicb.2018.00603 (2018).
 25. Castano-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study 
design. Gaceta sanitaria / S.E.S.P.A.S 29, 308–315, https://doi.org/10.1016/j.gaceta.2014.12.003 (2015).
 26. Waterboer, T. et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. 
Clinical chemistry 51, 1845–1853, https://doi.org/10.1373/clinchem.2005.052381 (2005).
7Scientific RepoRts |         (2019) 9:10847  | https://doi.org/10.1038/s41598-019-47347-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
We thank Shaynoor Dramsi and Camille Danne (Department of Microbiology, Institut Pasteur, Paris, France) for 
providing the purified proteins Gallo2178 and Gallo2179. This work was supported by the National Institutes of 
Health (grant number R01-CA93817, Ikuko Kato); The Netherlands Organization for Scientific Research (NWO 
016.166.089 to A.B.); the “Acción Transversal del Cáncer”, approved on the Spanish Ministry Council on the 11th 
October 2007; the Instituto de Salud Carlos III-FEDER funds –a way to build Europe- (grants numbers PI08/1770, 
PI08/0533, PI08/1359, PS09/00773, PS09/01662, PS09/01286, PS09/01903, PS09/02078, PI11/00226, PI11/01403, 
PI11/01810, PI11/01889, PI11/02213, PI12/00150, PI12/00265, PI12/00488, PI12/00715, PI12/01270, PI14/00613, 
PI17/00092); the Fundación Marques de Valdecilla (grant number API 10/09); Obra Social CAJASTUR (grant 
number SV-CAJASTUR-1); Recercaixa (grant number 2010ACUP 00310); Spanish Association Against Cancer 
(AECC) Scientific Foundation; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) –Generalitat de 
Catalunya (Catalonian Government) (grant numbers 2009SGR1026, 2009SGR1465 and 2017SGR723); and Junta 
de Castilla y León (grant number LE022A10-2). Sample collection and storage was partially supported by the 
Instituto de Salud Carlos III-FEDER (grant number RD09/0076/00036), Xarxa de Bancs de Tumors de Catalunya 
sponsored by Pla Director d’Oncologia de Catalunya (XBTC).
Author Contributions
J.B., A.B., N.A. and N.F. are responsible for the conception of the study, statistical analysis, interpretation of results 
and drafting the manuscript. V.M., B.P., V.M.o., T.D., J.C., G.F., P.A., D.S., J.A., J.J., J.H., S.S., R.C., M.K., M.P., N.A. 
are the principal investigators of the MCC-Spain study; I.K. is the principal investigator of the Detroit cohort; 
H.T. and A.B. are the principal investigators of the Nijmegen cohort; and responsible for the conception of the 
respective study and data collection. A.B., H.T. and R.R. were responsible for acquisition and analysis of ELISA 
data. J.B., M.P. and T.W. were responsible for acquisition and analysis of multiplex serology data. All authors have 
seen and approved the final version of the manuscript. J.B. is the guarantor.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47347-6.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
